

## Securities Release from Escrow

**Northridge, CA and Cambridge, United Kingdom, Perth, Australia, 31 March 2017** – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY) confirms that in accordance with ASX listing rule 3.10A, that 3,500,000 shares will be released from escrow on 14 April 2017.

### ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. approval trial is underway. To learn more, visit [www.avitamedical.com](http://www.avitamedical.com).

###

<p><b>Avita Medical Ltd</b>  Adam Kelliher  Chief Executive Officer  Phone: +44 020 8947 9804  <a href="mailto:akelliher@avitamedical.com">akelliher@avitamedical.com</a></p> <p><b>Avita Medical Ltd</b>  Tim Rooney  Chief Financial Officer  Phone: + 1 (818) 356-9400  <a href="mailto:trooney@avitamedical.com">trooney@avitamedical.com</a></p>	<p><b>Australia</b>  <b>Monsoon Communications</b>  Dean Felton  Phone: +61 (0)3 9620 3333  Mobile: +61 (0)411 698 499  <a href="mailto:deanf@monsoon.com.au">deanf@monsoon.com.au</a></p> <p><b>USA</b>  <b>Westwicke Partners</b>  Jamar Ismail  Phone +1 (415) 513-1282  <a href="mailto:jamar.ismail@westwicke.com">jamar.ismail@westwicke.com</a></p>
---	--